Entezari M, Flavarjani ZK, Ramezani A, et al. - Researchers examined the efficacy of three intravitreal bevacizumab (IVB) injections alone or in combination with intravitreal erythropoietin (EPO) for the treatment of refractory diabetic macular edema (DME). They conducted a randomized double-blind clinical trial enrolling 48 eyes of 34 diabetic patients with refractory DME. Either 3 monthly injections of 0.05 cc (1.25 mg) IVB plus 0.05 cc (1,000 unit) EPO or 0.05 cc (1.25 mg) IVB alone was administered in the eyes. Both groups exhibited insignificant mean best-corrected visual acuity changes up to 4 and 6 months. Outcomes revealed no additional effect of intravitreal erythropoietin to IVB in the treatment of refractory DME in the short term.